Paul Sakorafas

US Patent:

6509015, Jan 21, 2003

Filed:

Mar 31, 2000

Appl. No.:

09/540018

Inventors:

Jochen G. Salfeld - North Grafton MA
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA
Boris Labkovsky - Framingham MA
John A. Mankovich - Andover MA
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA
David Schoenhaut - Clifton NJ
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA
Alison J. Wilton - Cambridge, GB

Assignee:

BASF Aktiengesellschaft - Ludwigshafen

International Classification:

A61K 39395

US Classification:

4241421, 424 852, 4241451, 424800, 424810

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e. g. , K =10 M or less), a slow off rate for hTNF dissociation (e. g. , K =10 sec or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e. g. , in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

6914128, Jul 5, 2005

Filed:

Mar 24, 2000

Appl. No.:

09/534717

Inventors:

Jochen Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Melrose MA, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Little Shelford, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Stephen Smith - Ely, GB

Assignee:

Abbott GmbH & Co. KG - Wiesbaden

International Classification:

C07K016/18
C07K016/24
C12P021/08

US Classification:

5303873, 5303871, 5303879, 53038815, 53038824, 5303892, 530351

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

7223394, May 29, 2007

Filed:

Mar 7, 2001

Appl. No.:

09/801185

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - Cambridge, GB
Hendricus R. J. M. Hoogenboom - Maastricht, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Comberton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Garfield NJ, US
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Assignee:

Abbott Biotechnology Ltd - Hamilton

International Classification:

A61K 39/395

US Classification:

4241421, 4241451, 4241581, 53038815, 53038823, 5303892

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

7504485, Mar 17, 2009

Filed:

Jul 1, 2004

Appl. No.:

10/884830

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine J. Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB

Assignee:

Abbott GmbH & Co., KG - Wiesbaden

International Classification:

C07K 16/24
A61K 39/395

US Classification:

53038823, 4241451

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

7541031, Jun 2, 2009

Filed:

Apr 17, 2007

Appl. No.:

11/787901

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton Highlands MA, US
Hendricus R. J. M. Hoogenboom - Hasselt, BE
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Assignee:

Abbott Biotechnology Ltd.

International Classification:

A61K 39/395
A61K 31/495

US Classification:

4241421, 4241451, 4241581, 424810, 514249

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

7588761, Sep 15, 2009

Filed:

Sep 21, 2005

Appl. No.:

11/233252

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge MA, US

Assignee:

Abbott Biotechnology Ltd. - Hamilton

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241421, 4241451, 4241581, 424484, 424486, 424810, 53038815, 53038823, 530868

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

7883704, Feb 8, 2011

Filed:

Dec 22, 2006

Appl. No.:

11/645287

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden CT, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
John Gawain Elvin - Meldreth, GB
Alexander Robert Duncan - Carton, GB
Elaine Joy Derbyshire - Crowthorne, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Rønde, DK
Sarah Leila Du Fou - Hitchen, GB

Assignee:

Abbott GmbH & Co. KG - Wiesbaden

International Classification:

A61K 38/20
A61K 39/395
C07K 16/24
C12P 21/08

US Classification:

4241451, 53038823, 5303881, 5303891, 514 14, 4241301

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

US Patent:

8197813, Jun 12, 2012

Filed:

Mar 10, 2009

Appl. No.:

12/401469

Inventors:

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Assignee:

Abbott Biotechnology Ltd. - Hamilton

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241421, 4241451, 4241581, 53038815, 53038823

Abstract:

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.